Tobacco and bladder cancer in males: Increased risk for inhalers and smokers of black tobacco

Clavel, Jacqueline; Cordier, Sylvaine; Boccon‐Gibod, Liliane; Hémon, Denis

doi:10.1002/ijc.2910440408

Cited by 110 publications

(72 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Both mainstream and sidestream tobacco smoke contain nanogram quantities of carcinogenic aromatic amines, such as ortho-toluidine, 2-naphthylamine, and 4-ABP, for example, mainstream smoke from a nonfiltered cigarette contains 160, 1.7, and 4.6 nanograms of the respective chemicals (10,11). The elevated risk of bladder cancer in smokers is ascribed to their exposure to aromatic amines, with smokers of black (air cured) tobacco being at higher risk than smokers of blond (flue cured) tobacco (12)(13)(14). The latter finding accords with the richer content of aromatic amines in black tobacco products than blond tobacco products (10).…”

Section: Introductionmentioning

confidence: 99%

Organ Specificity of the Bladder Carcinogen 4-Aminobiphenyl in Inducing DNA Damage and Mutation in Mice

Yoon

Kim

Tommasi

et al. 2012

Cancer Prevention Research

View full text Add to dashboard Cite

Aromatic amines are a widespread class of environmental contaminants present in various occupational settings and tobacco smoke. Exposure to aromatic amines is a major risk factor for bladder cancer development. The etiologic involvement of aromatic amines in the genesis of bladder cancer is attributable to their ability to form DNA adducts, which upon eluding repair and causing mispairing during replication, may initiate mutagenesis. We have investigated the induction of DNA adducts in relation to mutagenesis in bladder and various nontarget organs of transgenic Big Blue mice treated weekly (i.p.) with a representative aromatic amine compound, 4-aminobiphenyl (4-ABP), for six weeks, followed by a six-week recovery period. We show an organ-specificity of 4-ABP in inducing repair-resistant DNA adducts in bladder, kidney, and liver of carcinogen-treated animals, which accords with the bioactivation pathway of this chemical in the respective organs. In confirmation, we show a predominant and sustained mutagenic effect of 4-ABP in bladder, and much weaker but significant mutagenicity of 4-ABP in the kidney and liver of carcinogentreated mice, as reflected by the elevation of background cII mutant frequency in the respective organs. The spectrum of mutations produced in bladder of 4-ABP-treated mice matches the known mutagenic properties of 4-ABP-DNA adducts, as verified by the preponderance of induced mutations occurring at G:C base pairs (82.9%), with the vast majority being G:C!T:A transversions (47.1%). Our data support a possible etiologic role of 4-ABP in bladder carcinogenesis and provide a mechanistic view on how DNA adduct-driven mutagenesis, specifically targeted to bladder urothelium, may account for organ-specific tumorigenicity of this chemical. Cancer Prev Res; 5(2); 299-308. Ó2011 AACR.

show abstract

Section: Introductionmentioning

confidence: 99%

Organ Specificity of the Bladder Carcinogen 4-Aminobiphenyl in Inducing DNA Damage and Mutation in Mice

Yoon

Kim

Tommasi

et al. 2012

Cancer Prevention Research

View full text Add to dashboard Cite

show abstract

“…The numbers are generally small, and the confidence intervals of the odds ratios are large; nevertheless, the qualitative consistency of the findings is intriguing (see also reference 4 for a review In a molecular epidemiology investigation in which we were involved (6), we reported that the quantities of hemoglobin adducts with 3-aminobiphenyl (3-ABP) and 4-ABP were related to the quantity of cigarettes smoked and, in the case of 4-ABP, also to the kind of tobacco smoked (air or flue cured). Air-cured tobacco is known to contain larger amounts of arylamines than flue-cured product and has also been found to be associated with higher risks of bladder cancer in three epidemiological investigations (7)(8)(9).…”

Section: Introductionmentioning

confidence: 99%

Interindividual variation in carcinogen metabolism and bladder cancer risk.

Víneis¹,

Ronco²

1992

Environ Health Perspect

View full text Add to dashboard Cite

Epidemiological studies indicate that subjects of the genetically based slow acetylator phenotype may be at higher risk for bladder cancer than fast acetylators, particularly when they are exposed to carcinogenic arylamines: N-acetylation is a detoxification step in the metabolism of some arylamines. We describe two collaborative studies on tobacco smoking, in which markers of internal dose (arylamine-hemoglobin adducts) and markers of genetically based metabolic polymorphism have been coupled. In the first investigation, we found that hemoglobin adducts formed by mononuclear arylamines have high reciprocal correlation coefficients, as do adducts from binuclear arylamines. This tendency of adducts with structurally similar arylamines to correlate reciprocally explains a large proportion ofthe residual variance seen after controlling for smoking habits (number and type of cigarettes). In the second study, the concentration of 4-aminobiphenyl-hemoglobin adducts varied according to three independent determinants: number of cigarettes, type of tobacco (air or flue cured), and acetylator phenotype (slow and fast). The dose-response relationship between the amount of tobacco smoked and level of 4-aminobiphenyl-hemoglobin adducts in the slow acetylators (with an immediate steep increase of the adducts) was different from that in the fast acetylators (with a more regular increase). These findings from "molecular epidemiology" may contribute to an understanding of the role of metabolic polymorphism in human carcinogenesis.

show abstract

“…Çalışmaya göre erkeklerde en sık görülen üçüncü kanser türü olup , tüm kanserler içindeki payı %8.5' tir. Kadınlarda ise 13. sı-radadır [3,4]. Mesane kanserinin %75-85' inde hastalık, mukoza (evre Ta-CIS) veya submukozaya (evre T1) sınırlıdır.…”

Section: Introductionunclassified

Recurrence and Progression Rate of High Grade Ta Bladder Cancer: 5-Year Follow up Results

Kılınç¹,

Sönmez²,

Ipek³

et al. 2015

Ann Clin Anal Med

View full text Add to dashboard Cite

ÖzetAmaç: Sunulan bu çalışmanın amacı yüksek dereceli Ta mesane kanseri olan hasta grubunda rekürrens, progresyon oranları ve BCG tedavisinin başarısını incelemek. Gereç ve Yöntem: 1997-2005 yılları arasında kliniğimizde histopatolojik tanısı yüksek dereceli Ta mesane kanseri saptanan 6 hafta BCG terapisi ile tedavi edilen primer mesane kanseri olan 48 hasta incelendi. Ortalama 55,6 aylık takip süresince, hastalar sistoskopi ve gerektiğinde TUR ile takip edildi. Bu hastaların rekürrens, derece ve evre progresyonu analiz edildi. Bulgular: 48 hastanın 8'inde (%16.6) rekürrens izlenmedi. 14 (% 29.1) hastada Ta hastada rekürrens gözlenirken 11 (%22.9) hastada T1 evresine progresyon izlendi. 5 (%31.25) hastada kasa invazyon gözlenerek progresyon saptandı. Üç hasta (%6) mesane kanserinden öldü. Tümör sayısı, cinsiyet, yaş ve tümör boyutu kas invazyonunu öngören faktörler olarak görülmedi. CIS birlikteliği progresyon ile büyük oranda bağlantılı saptandı (p<0.001). Tartışma: Bizim çalışmamız; neredeyse %50 rekürrens ve %30 progresyon oranları gözlenen yüksek dereceli Ta mesane kanserinin progresyon açısından yüksek potansiyele sahip olduğunu göstermiştir. Bu sonuçlarda yüksek dereceli T1 mesane kanseri çalışmalarının daha önceki sonuçları ile karşılaştırıldığında benzerlik saptanabilir. Biz en az 5 yıllık dönemde takip protokollerine titizlikle uyularak rekürrensin erken bir aşamada tespit edilmesi gerektiğini düşünüyoruz. Anahtar KelimelerKas İnvaziv Olmayan Mesane Kanseri; Progresyon; Rekürrens; Yüksek Dereceli Ta Abstract Aim: The aim of the present study to evaluate recurrence and progression rates and success of BCG therapy, in a population with high grade Ta bladder cancer. Material and Method: Of the 45 patients treated and follow up at our institution from 1997 to 2005 for the histopathological diagnosis of primary bladder cancer with high grade Ta bladder cancer were treated with BCG weekly for 6 weeks. At a follow up of mean 55,6 months patients were evaluated with urinary cytology, cystoscopy, transurethral resection and random mucosal biopsies. Recurrence, grade and stage progression were analyzed. Results: Of the 48 patients 8 (16,6%) responded positively to BCG without recurrence, while disease recurred as stage Ta in 14 (29,1%) and progressed as stage T1 in 11 (22,9% ) at a five-year follow up, and progressed to muscle layer infiltration in 15 (31,25%). Three (6%) patients died of bladder cancer. The number of tumors, gender, age and size of tumors did not appear to be predictive factors of progression to muscle invasion but an association with carcinoma in situ appeared to correlate highly with progression (p <0.001). Discussion: Our study demonstrates the high progression potential of high grade Ta bladder cancer, since nearly 50% recurred and 30 % progressed to invasive disease. These results may be closely compared with the results of previous trials of high grade T1 bladder cancer. We suggest that recurrence should be detected at an early stage using long-term follow up with strict observance of the ...

show abstract

Tobacco and bladder cancer in males: Increased risk for inhalers and smokers of black tobacco

Cited by 110 publications

References 15 publications

Organ Specificity of the Bladder Carcinogen 4-Aminobiphenyl in Inducing DNA Damage and Mutation in Mice

Organ Specificity of the Bladder Carcinogen 4-Aminobiphenyl in Inducing DNA Damage and Mutation in Mice

Interindividual variation in carcinogen metabolism and bladder cancer risk.

Recurrence and Progression Rate of High Grade Ta Bladder Cancer: 5-Year Follow up Results

Contact Info

Product

Resources

About